Lithium addition in antidepressant-resistant depression: Effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 5, 2007, Pages 1084-1088

  Birkenhäger, Tom K ^a   van den Broek, Walter W ^a   Fekkes, Durk ^a   Mulder, Paul G ^a   Moleman, Peter ^b   Bruijn, Jan A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Moleman Psychopharmacology   (Netherlands)

Author keywords

Lithium addition; Major depression; Plasma 5 HIAA; Plasma 5 HT; Platelet 5 HT

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; ANTIDEPRESSANT AGENT; FLUVOXAMINE; IMIPRAMINE; LITHIUM; SEROTONIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG EFFECT; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR DEPRESSION; MALE; MONOTHERAPY; SAMPLE; SEROTONIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANTIMANIC AGENTS; BLOOD PLATELETS; DEPRESSIVE DISORDER; DRUG RESISTANCE; FEMALE; FLUVOXAMINE; HUMANS; HYDROXYINDOLEACETIC ACID; IMIPRAMINE; LITHIUM COMPOUNDS; MALE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN;

EID: 34249285847     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.03.012     Document Type: Article

References (22)

1. Bauer M., and Dopfmer S. Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies. J Clin Psychopharmacol 19 (1999) 427-434
2. Bauer M., Adli M., Baethge C., Berghofer A., Sasse J., Heinz A., et al. Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry 48 (2003) 440-446
3. Birkenhäger T.K., van den Broek W.W., Mulder P.G., Bruijn J.A., and Moleman P. Comparison of two-phase treatment with imipramine or fluvoxamine, both followed by lithium addition, in inpatients with major depressive disorder. Am J Psychiatry 161 (2004) 2060-2065
4. Blier P., and de Montigny C. Short-term lithium administration enhances serotonergic neurotransmission: electrophysiological evidence in the rat CNS. Eur J Pharmacol 11 (1985) 69-77
5. Borgdorff P., Fekkes D., and Tangelder G.J. Hypotension caused by extracorporeal circulation: serotonin from pump-activated platelets triggers nitric oxide release. Circulation 106 (2002) 2588-2593
6. Celada P., Dolera M., Alvarez E., and Artigas F. Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement. J Affect Disord 25 (1992) 243-250
7. Cowen P.J., McCance S.L., Cohen P.R., and Julier D.L. Lithium increases 5-HT mediated neuroendocrine responses in tricyclic resistant depression. Psychopharmacology 99 (1989) 230-232
8. Cowen P.J., McCance S.L., Ware C.J., Cohen P.R., Chalmers J.S., and Dulier D.L. Lithium in tricyclic-resistant depression. Correlation of increased brain 5-HT function with clinical outcome. Br J Psychiatry 159 (1991) 341-346
9. de Montigny C., and Aghajanian G.I. Tricyclic antidepressants: long term treatment increases responsivity of rat forebrain neurones to serotonin. Science 202 (1978) 1303-1306
10. de Montigny C., Grunberg F., Mayer A., and Deschenes J.P. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 138 (1981) 252-256
11. Fekkes D., Timmerman L., and Pepplinkhuizen L. Effects of clomipramine on plasma amino acids and serotonergic parameters in panic disorder and depression. Eur Neuropsychopharmacol 4 (1997) 235-239
12. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9 suppl 1 (1994) 19-26
13. Manji H.K., Quiroz J.A., Sporn J., Payne J.L., Denicoff K., Gray N., et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry 53 (2003) 707-742
14. Mann J.J., McBride P.A., Anderson G.M., and Mieczkowski T.A. Platelet and whole blood serotonin content in depressed inpatients: correlations with acute and life-time psychopathology. Biol Psychiatry 32 (1992) 243-257
15. Martensson B., Wagner A., Beck O., Brodin K., Montero D., and Asberg M. Effects of clomipramine treatment on cerebrospinal fluid monoamine metabolites and platelet 3H-imipramine binding and serotonin uptake and concentration in major depressive disorder. Acta Psychiatr Scand 83 (1991) 125-133
16. McCance-Katz E., Price L.H., Charney D.S., and Heninger G.R. Serotonergic function during lithium augmentation of refractory depression. Psychopharmacology 108 (1992) 93-97
17. Muhlbauer H.D., and Muller-Oerlinghausen B. Fenfluramine stimulation of serum cortisol in patients with major affective disorders and healthy controls: further evidence for a central serotonergic action of lithium in man. J Neural Transm 61 (1985) 81-94
18. Price L.H., Charney D.S., Delgado P.L., Goodman W.K., Krystal J.H., Woods S.W., et al. Clinical studies of 5-HT function using IV l-tryptophan. Prog Neuropsychopharmacol Biol Psychiatry 14 (1990) 459-472
19. Sarrias M.J., Cabre P., Martinez E., and Artigas F. Relationship between serotonergic measures in blood and cerebrospinal fluid simultaneously obtained in humans. J Neurochem 54 (1990) 783-786
20. Spitzer R.L., and Endicott J. Schedule for affective disorders and schizophrenia-lifetime version. 3rd ed. (1978), New York State Psychiatric Institute, Biometrics Research, New York
21. Spreux-Varoquaux O., Gailledreau J., Vanier B., Bothua D., Plas J., Chevalier J.F., et al. Initial increase of plasma serotonin: a biological predictor for antidepressant response to clomipramine?. Biol Psychiatry 40 (1996) 465-473
22. van Praag H.M. Can stress cause depression?. World J Biol Psychiatry 6 Suppl. 2 (2005) 5-22